# Silybin

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/silybin
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 8 / 10
**Category:** Compound
**Also Known As:** Silibinin, Silybum marianum extract, Milk thistle flavonolignan, Silybin A, Silybin B, Hepatoprotective flavonoid, Silymarin bioactive

## Overview

Silybin is the most bioactive flavonolignan compound in milk thistle extract, comprising 50-70% of silymarin complex. It functions as a potent [hepatoprotective](/ingredients/condition/detox) agent by stabilizing hepatocyte membranes and reducing [oxidative stress](/ingredients/condition/antioxidant) through antioxidant pathways.

## Health Benefits

• Reduces liver enzymes in NAFLD patients: Meta-analysis of 8 RCTs showed AST reduction of 6.57 U/L and ALT reduction of 9.16 U/L (moderate evidence)
• May improve chemotherapy-induced liver changes: One RCT found reduced hepatic involvement on ultrasonography in breast cancer patients (preliminary evidence)
• Shows antioxidant effects: Reduces [oxidative stress](/ingredients/condition/antioxidant) markers like malondialdehyde in liver cells (mechanistic evidence)
• Demonstrates antifibrotic properties: Modulates hepatic pathways related to fibrosis, though clinical trials show mixed results (conflicting evidence)
• Exhibits potential [antiviral](/ingredients/condition/immune-support) activity: IV silibinin showed efficacy in HCV non-responders, though oral forms lacked effect (form-dependent evidence)

## Mechanism of Action

Silybin stabilizes hepatocyte cell membranes by binding to phospholipids and preventing [lipid peroxidation](/ingredients/condition/antioxidant). It activates nuclear factor erythroid 2-related factor 2 (Nrf2) pathways to enhance antioxidant enzyme production including [glutathione](/ingredients/condition/detox) peroxidase and superoxide dismutase. The compound also inhibits nuclear factor kappa B (NF-κB) activation, reducing [inflammatory](/ingredients/condition/inflammation) cytokine production in liver tissue.

## Clinical Summary

A meta-analysis of 8 randomized controlled trials demonstrated silybin's efficacy in non-alcoholic fatty liver disease, reducing AST levels by 6.57 U/L and ALT levels by 9.16 U/L compared to placebo. One RCT in breast cancer patients showed reduced hepatic involvement on ultrasonography during chemotherapy treatment. Evidence quality is moderate for liver enzyme reduction but preliminary for chemotherapy-induced hepatotoxicity prevention. Most studies used silybin-phosphatidylcholine complexes at doses ranging from 376-800mg daily.

## Nutritional Profile

Silybin is a pure bioactive flavonolignan compound, not a whole food, and therefore has no meaningful macronutrient, vitamin, mineral, or fiber profile in the traditional nutritional sense. Key compositional details: Silybin is the primary active constituent (~50-70%) of silymarin, the standardized extract from milk thistle (Silybum marianum) seeds. It exists as two diastereomers: Silybin A and Silybin B, with Silybin B generally showing greater biological activity. Molecular weight: 482.44 g/mol. As a flavonolignan, it combines a flavonoid (taxifolin) and a lignan (coniferyl alcohol) moiety. Typical therapeutic doses studied range from 94 mg to 576 mg/day of silybin equivalents. Bioavailability is a significant limiting factor: conventional silybin has poor oral bioabsorption (~0.73-1% in some models) due to low water solubility and limited [intestinal permeability](/ingredients/condition/gut-health). Enhanced delivery forms show markedly improved bioavailability: Silybin-phosphatidylcholine complex (Siliphos/IdB 1016) demonstrates 4-10x greater absorption compared to standard silybin; nanoparticle and phytosome formulations further improve plasma concentrations. Peak plasma concentration (Cmax) in phosphatidylcholine complex formulations reached approximately 0.5-1.0 µg/mL at doses of 360 mg. Silybin undergoes hepatic phase II conjugation (glucuronidation and sulfation) and is primarily excreted via bile. No caloric contribution is expected at therapeutic doses.

## Dosage & Preparation

Clinically studied oral doses range from 420-2100 mg/day of standardized silymarin extract (containing ~70% flavonolignans). Common regimens include: NASH treatment 420-700 mg/day or 700 mg three times daily; chemotherapy support 140 mg three times daily; chronic liver disease 160-360 mg/day of silybin or phytosome formulations. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Silybin is generally well-tolerated with mild gastrointestinal side effects including nausea, diarrhea, and abdominal discomfort reported in less than 5% of users. It may enhance the absorption of certain medications by inhibiting P-glycoprotein transporters, potentially increasing drug concentrations. Silybin can interact with diabetes medications by enhancing glucose uptake, requiring blood sugar monitoring. Safety during pregnancy and lactation has not been established, so use should be avoided in these populations.

## Scientific Research

Large Phase II trials in NASH patients (NCT00680407, PMID: 31536511; NCT02006498, PMID: 28419855) using 420-2100 mg/day silymarin showed no significant improvement in primary endpoints, though a meta-analysis (PMID: 29245314) found modest transaminase reductions. A triple-blind RCT in breast cancer patients (PMID: 33861657) suggested potential [hepatoprotective](/ingredients/condition/detox) effects during chemotherapy.

## Historical & Cultural Context

Milk thistle (Silybum marianum) and its silymarin/silybin extracts have been used in traditional European herbal medicine for centuries to treat liver and gallbladder disorders. Historical use dates to ancient Greece, with the herb persisting in Western folk medicine specifically for [hepatoprotect](/ingredients/condition/detox)ion.

## Synergistic Combinations

Phosphatidylcholine (for enhanced bioavailability), N-acetylcysteine, Alpha-lipoic acid, Vitamin E, Artichoke extract

## Frequently Asked Questions

### Does silybin help with NAFLD or fatty liver disease?

Silybin shows modest benefit for non-alcoholic fatty liver disease (NAFLD). A meta-analysis of 8 RCTs (PMID: 29245314) found it reduced AST by approximately 6.57 U/L and ALT by 9.16 U/L in NAFLD patients. However, large Phase II trials using 420–2100 mg/day of standardised silymarin did not meet primary endpoints for NASH improvement. The mechanisms involve Nrf2 pathway activation, reduced lipid peroxidation, and NF-κB inhibition. Silybin may offer supportive benefit alongside lifestyle changes, but is not a standalone treatment for fatty liver.

### What are the side effects of taking silybin supplements?

Silybin is generally well tolerated at clinically studied doses. Reported side effects are typically mild and may include gastrointestinal discomfort such as nausea, bloating, or loose stools, particularly at higher doses of 700 mg three times daily. Allergic reactions are rare but possible, especially in individuals sensitive to plants in the Asteraceae family. Silybin has a low toxicity profile in human trials, with Phase II studies using up to 2100 mg/day of silymarin extract reporting no serious adverse events attributable to the compound.

### Is silybin effective for liver protection during chemotherapy?

Preliminary evidence suggests silybin may help protect the liver during chemotherapy. A triple-blind RCT in breast cancer patients (PMID: 33861657) found that supplementation with silybin at 140 mg three times daily was associated with reduced hepatic involvement as measured by ultrasonography compared to placebo. The proposed mechanism involves Nrf2-mediated antioxidant enzyme upregulation and NF-κB inhibition reducing inflammatory damage. Evidence remains preliminary and patients undergoing chemotherapy should consult their oncologist before adding silybin to their regimen.

### Can silybin reverse liver fibrosis?

Silybin demonstrates antifibrotic properties in mechanistic studies by modulating hepatic signalling pathways associated with fibrosis development, including inhibition of hepatic stellate cell activation. However, clinical trial results are mixed. While in vitro and animal data are promising, human trials have not consistently demonstrated significant reversal of fibrosis. Silybin is more supported for reducing liver enzyme elevations and oxidative stress than for reversing established fibrotic changes. More rigorous clinical trials with fibrosis-specific endpoints are needed before strong conclusions can be drawn.

### Can I take silybin with medications for liver disease or statins?

Silybin can interact with certain medications due to its effects on cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9. This may alter the metabolism of statins, anticoagulants like warfarin, and immunosuppressants such as tacrolimus. In individuals already taking hepatotoxic drugs, silybin may offer some liver protection, but the interaction potential means dose adjustments could be necessary. Always consult a healthcare provider or pharmacist before combining silybin with prescription medications, especially those with narrow therapeutic windows.

### Is silybin phytosome more effective than standard silybin?

Yes, silybin phytosome formulations demonstrate significantly improved bioavailability compared to standard silybin. Silybin is poorly absorbed in conventional forms due to its low aqueous solubility. Phytosome technology binds silybin to phosphatidylcholine, enhancing intestinal absorption and hepatic uptake. Clinical dosing for phytosome formulations is typically 160–360 mg/day, which is lower than the 420–700 mg/day used for standard silymarin extracts. For individuals seeking therapeutic liver benefits from oral supplementation, phytosome forms may offer more efficient delivery per milligram consumed.

### Does silybin have antioxidant properties and how do they work?

Silybin is a potent antioxidant that works through multiple mechanisms. It activates the Nrf2 pathway, stimulating production of endogenous antioxidant enzymes including glutathione peroxidase and superoxide dismutase. It also directly scavenges reactive oxygen species and prevents lipid peroxidation by binding to phospholipids in hepatocyte cell membranes. Clinical studies have measured reductions in oxidative stress markers such as malondialdehyde in liver tissue following silybin supplementation. These antioxidant actions underpin many of its hepatoprotective effects observed in NAFLD and chemotherapy-related liver stress research.

### Does oral silybin work for hepatitis C treatment?

Oral silybin does not appear effective for hepatitis C treatment. While intravenous silibinin showed clinical efficacy in HCV patients who did not respond to standard antiviral therapy, human trials using oral silybin formulations failed to replicate these antiviral effects. This discrepancy is attributed to the poor oral bioavailability of standard silybin limiting achievable plasma concentrations needed for antiviral activity. With highly effective direct-acting antiviral medications now available for HCV, oral silybin is not considered a viable antiviral treatment option and should not replace prescribed antiviral therapy.

### What is the difference between silybin and silymarin?

Silybin is the primary active compound comprising 50-70% of silymarin extract. Silymarin is the complete flavonolignan complex from milk thistle containing silybin, silychristin, silydianin, and isosilybin.

### How much silybin should I take for liver support?

Clinical studies typically use 376-800mg daily of silybin-phosphatidylcholine complex for liver support. The phosphatidylcholine complex improves absorption compared to standard silybin extracts.

### How long does silybin take to reduce liver enzymes?

Meta-analysis data shows significant AST and ALT reductions typically occur after 8-12 weeks of consistent silybin supplementation. Individual response may vary based on underlying liver condition severity.

### Can silybin help with alcohol-related liver damage?

While silybin shows hepatoprotective properties, most clinical evidence focuses on non-alcoholic fatty liver disease. Limited studies suggest potential benefits for alcohol-related liver damage, but more research is needed.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*